Title for MeetingAbstracts
Alphabetical listing of titles
-
Status report on HIV diagnosis rates in older adults in the United States - rates decline or remain stable.
-
Statutory and voluntary sector involvement in the development of strategies for HIV prevention with African communities.
-
Staving off increases in young gay/bisexual men's risk behavior in the HAART era.
-
Stavudine ( D4T ) in HIV infected patients with CD4 less than 350/mm3: results of a double-blind randomized placebo controlled study.
-
Stavudine (d4T) a promising anti-retroviral agent.
-
Stavudine (d4T) and didanosine (ddI) combination therapy in HIV-infected subjects: antiviral effect and safety in an on-going pilot randomized double-blinded trial.
-
Stavudine (d4T) and Lamivudine (3TC) Triphosphate in HIV-Infected Patients with or without Prior Zidovudine (ZDV) Experience.
-
Stavudine (d4T) in the therapy of patients with advanced AIDS and less than 50 CD4 cells.
-
Stavudine (d4T), didanosine (ddI) and ritonavir as a triple therapy in antiretroviral-naive patients: results at 72 weeks. The IMEA 01 Study Group.
-
Stavudine (d4T), didanosine (ddI), and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study.
-
Stavudine (d4T), didanosine (ddI), and nelfinavir combination therapy in pretreated HIV-patients: antiviral effect and safety in an ongoing study.
-
Stavudine (d4T), lamivudine (3TC), and nevirapine (NVP) combination regimen: large scale implementation with or without enough evidence?
-
Stavudine (d4T), nelfinavir (NFV) and nevirapine (NVP): preliminary safety, activity and pharmacokinetic (PK) interactions.
-
Stavudine (d4T), nelfinavir (NFV) and nevirapine (NVP): suppression of HIV-1 RNA to fewer than 50 copies/ml during 5 months of therapy.
-
Stavudine (d4T)-HIV 1 viral load and CD4 positive cell count in HIV+ individuals pretreated with zidovudine.
-
Stavudine entry into cerebrospinal fluid of HIV-infected subjects after single and multiple doses.
-
Stavudine extended release (XR*): single-dose, dose-proportionality study following oral administration in healthy subjects.
-
Stavudine Extended Release Formulation and Tenofovir Disoproxil Fumarate: Lack of a Pharmacokinetic Drug Interaction.
-
Stavudine extended/prolonged release (XR/PRC) vs stavudine immediate release (IR) in combination with lamivudine and efavirenz: 48 week efficacy and safety.
-
Stavudine in combination therapies reduces cerebrospinal fluid HIV-1 RNA levels to below detection limit during 3-9 months follow-up. Neuroscience of HIV Infection.
-
Stavudine penetrates the blood-brain barrier.
-
Stavudine stops neuro-AIDS in AZT-non-responders.
-
Stavudine XR vs Stavudine IR as Part of Potent Antiretroviral Combination Therapy: 24-Week Safety and Antiviral Efficacy.
-
Stavudine(D4T, ZERIT) sensitivities in clinical HIV isolates obtained from a pediatric population. American Pediatric Association and Society for Pediatric Research annual meeting; 1996 May 6-10; Washington, D.C.
-
Stavudine, Lamivudine and Abacavir regimen in HIV Infected Asymptomatic Adults previously treated with AZT-3TC regimen.
-
Stavudine, lamivudine, and indinavir in drug users and non-drug users: adherence, side effects, and efficacy.
-
Stavudine-didanosine-nevirapine: a convenient highly active triple combination for first line antiretroviral therapy.
-
Stavudine/Didanosine - switch to Tenofovir: course of metabolic changes.
-
Stavudine/od and didanosine/nevirapine in antiretroviral-naive HIV-1-infected patients: a convenient triple combination regimen.
-
Staying a caring provider in the long haul.